Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 16,122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Recruiting No phase listed Observational

Safe and Explainable AI

NCT06694181
View directory record Official record
Conditions
Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions
AI-PERSONALIZED CLINICAL DECISION SUPPORT
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 30, 2026, 10:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

NCT02874430
View directory record Official record
Conditions
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma
Interventions
Metformin Hydrochloride, Doxycycline
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

NCT04140292
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy (PDT), Vitamin D3
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 30, 2026, 10:08 AM EDT
Completed No phase listed Observational

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

NCT01974232
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Months to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status

NCT00194363
View directory record Official record
Conditions
Lymphedema
Interventions
Strength training
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Apremilast
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 4 Interventional

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT06806657
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Garadacimab
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Litchfield Park, Arizona • Bentonville, Arkansas • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

NCT00281957
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
sorafenib tosylate, tipifarnib, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
173
States / cities
Little Rock, Arkansas • Castro Valley, California • Fremont, California + 113 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

NCT00936221
View directory record Official record
Conditions
Melanoma
Interventions
AZD6244, Dacarbazine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Solution for the Treatment of Oral Lichen Planus

NCT02850601
View directory record Official record
Conditions
Lichen Planus
Interventions
Dexamethasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 3 Interventional

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

NCT03073967
View directory record Official record
Conditions
HSV Infection
Interventions
Pritelivir, Investigator's choice
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
16 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 30, 2026, 10:08 AM EDT
Withdrawn Phase 2 Interventional

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

NCT00003536
View directory record Official record
Conditions
Stage IV Breast Cancer, Recurrent Breast Cancer
Interventions
antineoplaston A10, methotrexate, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, chemotherapy, complementary and alternative therapy, differentiation therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 30, 2026, 10:08 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis
Interventions
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Gainesville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

NCT00885534
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Cisplatin, Vinblastine, Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

NCT00634634
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sorafenib, Letrozole
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 30, 2026, 10:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709
View directory record Official record
Conditions
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions
BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

NCT00003509
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

NCT02571998
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Omiganan (CLS001) Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
12 Years and older · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Santa Ana, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 3 Interventional

Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child

NCT00194571
View directory record Official record
Conditions
Breast Cancer
Interventions
Educational counseling intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 30, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

Mepolizumab in Episodic Angioedema With Eosinophilia

NCT04128371
View directory record Official record
Conditions
Eosinophilia, Angioedema
Interventions
mepolizumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 30, 2026, 10:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer

NCT02549534
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Axon Reflexes, Axon Flares, Self-Reported Signs & Symptoms of CIPN
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 30, 2026, 10:08 AM EDT
Terminated Phase 1 Interventional

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

NCT06299163
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
Interventions
NM32-2668
Biological
Lead sponsor
Numab Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

NCT02804763
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Placebo, Dapirolizumab pegol (DZP)
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 30, 2026, 10:08 AM EDT